Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "NMDA-receptor"

3 News Found

Exciva initiates Phase 2/3 SERENADA trial for Alzheimer’s agitation therapy
Clinical Trials | April 29, 2026

Exciva initiates Phase 2/3 SERENADA trial for Alzheimer’s agitation therapy

The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation

GRIN Therapeutics launches global Phase 3 trial for groundbreaking GRIN-NDD therapy
Clinical Trials | January 14, 2026

GRIN Therapeutics launches global Phase 3 trial for groundbreaking GRIN-NDD therapy

GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today

AbbVie to acquire Gilgamesh Pharmaceuticals’ bretisilocin for $1.2 billion
News | August 28, 2025

AbbVie to acquire Gilgamesh Pharmaceuticals’ bretisilocin for $1.2 billion

Latest Stories

Kahimmune Therapeutics signs agreement for scientific collaboration with Gustave Roussy

Leinco Technologies and CellCarta partner to advance proteomics in immuno-oncology

Sanofi Consumer Healthcare reports 33% revenue growth in Q1 FY26; PAT rises 36%

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics
Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics
Dr Maloy Ghosh Chief Scientific Officer, Zumutor Biologics
The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings
The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings
Venkat Nelabhotla Co-Founder, President & CEO, Vyome Holdings, Inc.
Local manufacturing, deeper CDMO ties, region-specific solutions remain our top priorities in next 3–5 years: Ganesh Bade, Director Bioprocessing–IMEA, Avantor
Local manufacturing, deeper CDMO ties, region-specific solutions remain our top priorities in next 3–5 years: Ganesh Bade, Director Bioprocessing–IMEA, Avantor
Ganesh Bade Head Bioprocessing, India, Avantor

Packaging